| 0.48 -0.02 (-4%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 0.81 | 1-year : | 1.1 |
| Resists | First : | 0.69 | Second : | 0.94 |
| Pivot price | 0.37  |
|||
| Supports | First : | 0.29 | Second : | 0.24 |
| MAs | MA(5) : | 0.45 |
MA(20) : | 0.36 |
| MA(100) : | 0.48 |
MA(250) : | 0.59 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 32.5 |
D(3) : | 40.4 |
| RSI | RSI(14): 60.1 |
|||
| 52-week | High : | 1.12 | Low : | 0.29 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ XCUR ] has closed below upper band by 19.3%. Bollinger Bands are 116.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 5 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 0.58 - 0.58 | 0.58 - 0.58 |
| Low: | 0.43 - 0.43 | 0.43 - 0.43 |
| Close: | 0.47 - 0.48 | 0.48 - 0.48 |
Exicure, Inc., a biotechnology company, develops therapies for neurological disorders and hair loss based on its proprietary spherical nucleic acid (SNA) technology. Its lead program candidate includes SCN9A that is in preclinical studies for neuropathic and chronic pain. The company has a collaboration, option, and license agreement with AbbVie Inc. to develop SNA-based treatments for hair loss disorders; and collaboration agreement with Ipsen S.A. to research, develop, and commercialize novel spherical nucleic acids for Huntington's disease and Angelman syndrome. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.
Sat, 20 Jul 2024
Exicure (NASDAQ:XCUR) Trading 76% Higher - Defense World
Mon, 17 Jun 2024
Exicure, Inc. Reports First Quarter 2024 Financial Results - Business Wire
Mon, 17 Jun 2024
Exicure, Inc. Reports First Quarter 2024 Financial Results - StockTitan
Thu, 23 May 2024
Exicure faces Nasdaq delisting over filing delays - Investing.com
Thu, 23 May 2024
Exicure, Inc. Received Nasdaq Notice of a Delisting Determination - Business Wire
Thu, 16 May 2024
Exicure, Inc. Reports Third Quarter 2023 Financial Results - Business Wire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 9 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 45 (%) |
| Held by Institutions | 10.3 (%) |
| Shares Short | 162 (K) |
| Shares Short P.Month | 274 (K) |
| EPS | -1.51 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.25 |
| Profit Margin | 0 % |
| Operating Margin | -167.2 % |
| Return on Assets (ttm) | -37.5 % |
| Return on Equity (ttm) | -158.6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.05 |
| EBITDA (p.s.) | -1.16 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -7 (M) |
| Levered Free Cash Flow | -4 (M) |
| PE Ratio | -0.32 |
| PEG Ratio | 0 |
| Price to Book value | 1.91 |
| Price to Sales | 8.3 |
| Price to Cash Flow | -0.56 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|